Introducing the American Society of Neuroradiology PET-Guided Diagnosis and Management in Neuro-Oncology Study Group

References

1. 1.↵
   1. Smith NJ,
   2. Deaton TK,
   3. Territo W, et al

   . Hybrid (18)F-fluoroethyltyrosine PET and MRI with perfusion to distinguish disease progression from treatment-related change in malignant brain tumors: the quest to beat the toughest cases. J Nucl Med 2023;64:1087–92 doi:10.2967/jnumed.122.265149 pmid:37116915

   Abstract/FREE Full Text
2. 2.↵
   1. Nabavizadeh A,
   2. Bagley SJ,
   3. Doot RK, et al

   . Distinguishing progression from pseudoprogression in glioblastoma using (18)F-Fluciclovine PET. J Nucl Med 2023;64:852–58 doi:10.2967/jnumed.122.264812 pmid:36549916

   Abstract/FREE Full Text
3. 3.↵
   1. Law I,
   2. Albert NL,
   3. Arbizu J, et al

   . Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [¹⁸F] FDG: version 1.0. Eur J Nucl Med Mol Imaging 2019;46:540–57 doi:10.1007/s00259-018-4207-9 pmid:30519867

   CrossRefPubMed
4. 4.↵
   1. Albert NL,
   2. Weller M,
   3. Suchorska B, et al

   . Response Assessment in Neuro-Oncology Working Group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. Neuro Oncol 2016;18:1199–208 doi:10.1093/neuonc/now058 pmid:27106405

   CrossRefPubMed
5. 5.↵
   1. Galldiks N,
   2. Lohmann P,
   3. Fink GR, et al

   . Amino acid PET in neurooncology. J Nucl Med 2023;64:693–700 doi:10.2967/jnumed.122.264859 pmid:37055222

   Abstract/FREE Full Text
6. 6.↵
   1. Galldiks N,
   2. Albert NL,
   3. Sommerauer M, et al

   . PET imaging in patients with meningioma-report of the RANO/PET Group. Neuro Oncol 2017;19:1576–87 doi:10.1093/neuonc/nox112 pmid:28605532

   CrossRefPubMed
7. 7.↵
   1. Ivanidze J,
   2. Roytman M,
   3. Skafida M, et al

   . Dynamic (68)Ga-DOTATATE PET/MRI in the diagnosis and management of intracranial meningiomas. Radiol Imaging Cancer 2022;4:e210067 doi:10.1148/rycan.210067 pmid:35275019

   CrossRefPubMed
8. 8.↵
   1. Darcourt J,
   2. Chardin D,
   3. Bourg V, et al

   . Added value of [¹⁸F]FDOPA PET to the management of high-grade glioma patients after their initial treatment: a prospective multicentre study. Eur J Nucl Med Mol Imaging 2023;50:2727–35 doi:10.1007/s00259-023-06225-0 pmid:37086272

   CrossRefPubMed
9. 9.↵
   1. Mankoff DA,
   2. Edmonds CE,
   3. Farwell MD, et al

   . Development of companion diagnostics. Semin Nucl Med 2016;46:47–56 doi:10.1053/j.semnuclmed.2015.09.002 pmid:26687857

   CrossRefPubMed
10. 10.↵
    1. Ivanidze J,
    2. Subramanian K,
    3. Youn T, et al

    . Utility of [¹⁸F]-fluoroestradiol (FES) PET/CT with dedicated brain acquisition in differentiating brain metastases from posttreatment change in estrogen receptor-positive breast cancer. Neurooncol Adv 2021;3:vdab178 doi:10.1093/noajnl/vdab178 pmid:34988456

    CrossRefPubMed
11. 11.↵
    1. Burkett BJ,
    2. Bartlett DJ,
    3. McGarrah PW, et al

    . A review of theranostics: perspectives on emerging approaches and clinical advancements. Radiol Imaging Cancer 2023;5:e220157 doi:10.1148/rycan.220157 pmid:37477566

    CrossRefPubMed
12. 12.↵
    1. Kersch CN,
    2. Ambady P,
    3. Hamilton BE, et al

    . MRI and PET of brain tumor neuroinflammation in the era of immunotherapy, from the AJR Special Series on Inflammation. AJR Am J Roentgenol 2022;218:582–96 doi:10.2214/AJR.21.26159 pmid:34259035

    CrossRefPubMed
13. 13.↵
    1. Galldiks N,
    2. Langen KJ,
    3. Albert NL, et al

    . Investigational PET tracers in neuro-oncology: what's on the horizon? A report of the PET/RANO group. Neuro Oncol 2022;24:1815–26 doi:10.1093/neuonc/noac131 pmid:35674736

    CrossRefPubMed